Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).
Roger M. Lyons(Hematology Oncology Associates), Dietmar Berger(Amgen (United States)), Richard Lizambri(Amgen (United States)), Romeo A. Mandanas, Ralph V. Boccia(Center for Cancer and Blood Disorders), Xuena Wang(Tianjin University of Traditional Chinese Medicine), Gail Macik(University of Virginia)
Cited by 3
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425